| SHL to speak at Drug Delivery System Development and Lifecycle Management Requirements for Biologic Pharmaceuticals: Trends and Best Practices | ||||
|
|
This is Lucio Giambattista’s first time to speak at the event and he will be joined by a panel of speakers for the afternoon session on March 16th from 1:15-4:30 pm in the Empire Room. Commenting on the event, Lucio Giambattista said, “Speaking at the Biologic Forum session of DCAT will give speakers the opportunity to share experiences and attendees the chance to ask questions that are relevant to their respective companies. This market is changing rapidly and as a medical device manufacturer we have a responsibility to attend events such as these to overview trends, key considerations and best practices with the interests of the end-user in mind.” Lucio is currently Executive Vice President for the SHL Group and Managing Director of SHL Medical in the USA. One of his latest responsibilities includes establishing SHL Pharma Systems, a production facility offering final assembly and packaging services in the USA. His contributions to this project also mean that he will be responsible for expanding these services internationally in Europe and Asia over the coming years. Prior to joining SHL, Lucio worked for 11 years with Becton Dickinson as Associate Director of Self Injection Systems. He holds a BSME/MSME from the New Jersey Institute of Technology and has been granted several patents for pen injector and auto injector products. For more information about this event and related speakers please go to: http://www.dcat.org/Pages/progr_ShowProgram.aspx?IDProgram=72
About SHL SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. We have over 1,600 staff globally (1000 staff in Taiwan), with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia. SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities. Our organization consists of three distinct group companies: SHL Medical SHL Healthcare SHL Technologies For additional information visit www.shl-group.com or contact us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it SHL Media Contact |
February 22, 2011 [Taoyuan, Taiwan]: The 2011 DCAT Biologics Forum will focus on trends and best practices for subcutaneous biologic drug delivery systems featuring presentations and discussion with leaders from the FDA, pharma and delivery system component supplier markets. Several key industry experts have been invited to speak at this event which will be held from March 14th - 17th at the Waldorf-Astoria Hotel in New York City.